Literature DB >> 32404952

Chronic myeloid leukemia with insertion-derived BCR-ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis.

Zhenya Tang1, Gokce A Toruner2, Guilin Tang2, C Cameron Yin2, Wei Wang2, Shimin Hu2, Beenu Thakral2, Sa A Wang2, Roberto N Miranda2, Joseph D Khoury2, L Jeffrey Medeiros2.   

Abstract

Chromosomal insertion-derived BCR-ABL1 fusion is rare and mostly cryptic in chronic myeloid leukemia (CML). Most of these cases present a normal karyotype, and their risk and/or prognostic category are uncertain. We searched our database and identified 41 CML patients (20 M/21 F, median age: 47 years, range 12-78 years) with insertion-derived BCR-ABL1 confirmed by various FISH techniques: 31 in chronic phase, 1 in accelerated phase, and 9 in blast phase at time of diagnosis. Conventional cytogenetics analysis showed a normal karyotype (n = 19); abnormal karyotype with morphologically normal chromosomes 9 and 22 (n = 5); apparent ins(9;22) (n = 2) and abnormal karyotype with apparent abnormal chromosomes 9, der(9) and/or 22, der(22) (n = 15). The locations of insertion-derived BCR-ABL1 were identified on chromosome 22 (68.3%), 9 (29.3%), and 19 (2.4%). Complex chromosomal abnormalities were often overlooked by conventional cytogenetics but identified by FISH tests in many cases. After a median follow-up of 58 months (range 1-242 months), 11 patients died, and 3 lost contact, while the others achieved different cytogenetic/molecular responses. The locations of BCR-ABL1 (der(22) vs. non-der(22)) and the karyotype results (complex karyotype vs. noncomplex karyotype) by conventional cytogenetics were not associated with overall survival in this cohort. However, redefining the complexity of chromosomal abnormality by correlating karyotype and FISH findings, CML cases with simple chromosomal abnormalities had a more favorable overall survival than that with complex chromosomal abnormalities. We conclude that insertion-derived BCR-ABL1 fusions often involve complex chromosomal abnormalities which are overlooked by conventional cytogenetics, but can be identified by one or more FISH tests. We also suggest that the traditional cytogenetic response criteria may not apply in these patients, and the complexity of chromosomal abnormalities redefined by correlating karyotype and FISH findings can plays a role in stratifying patients into more suitable risk groups for predicting prognosis. (Word count: 292).

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32404952     DOI: 10.1038/s41379-020-0564-6

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  57 in total

1.  Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia.

Authors:  P B Sinclair; E P Nacheva; M Leversha; N Telford; J Chang; A Reid; A Bench; K Champion; B Huntly; A R Green
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

2.  A FISH study of variant Philadelphia rearrangements.

Authors:  K S Reddy; V Sulcova
Journal:  Cancer Genet Cytogenet       Date:  2000-04-15

3.  Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia.

Authors:  Zihai Li; Yi Qiao; Bei Liu; Elizabeth J Laska; Priyamvadha Chakravarthi; Judith M Kulko; Robert D Bona; Min Fang; Upendra Hegde; Victor Moyo; Susan H Tannenbaum; Antoine Ménoret; Judy Gaffney; Laura Glynn; Carolyn D Runowicz; Pramod K Srivastava
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

Review 4.  Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

Authors:  F Bonifazi; A de Vivo; G Rosti; F Guilhot; J Guilhot; E Trabacchi; R Hehlmann; A Hochhaus; P C Shepherd; J L Steegmann; H C Kluin-Nelemans; J Thaler; B Simonsson; A Louwagie; J Reiffers; F X Mahon; E Montefusco; G Alimena; J Hasford; S Richards; G Saglio; N Testoni; G Martinelli; S Tura; M Baccarani
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

5.  Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia.

Authors:  B J Huntly; A G Reid; A J Bench; L J Campbell; N Telford; P Shepherd; J Szer; H M Prince; P Turner; C Grace; E P Nacheva; A R Green
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

6.  On the genesis and prognosis of variant translocations in chronic myeloid leukemia.

Authors:  Madhavi Gorusu; Peter Benn; Zihai Li; Min Fang
Journal:  Cancer Genet Cytogenet       Date:  2007-03

7.  Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia.

Authors:  Alistair G Reid; Brian J P Huntly; Colin Grace; Anthony R Green; Elisabeth P Nacheva
Journal:  Br J Haematol       Date:  2003-05       Impact factor: 6.998

Review 8.  Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia.

Authors:  Brian J P Huntly; Anthony Bench; Anthony R Green
Journal:  Blood       Date:  2003-05-01       Impact factor: 22.113

9.  Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.

Authors:  Brian J P Huntly; Francois Guilhot; Alistair G Reid; George Vassiliou; Evelin Hennig; Christina Franke; Jennie Byrne; Andre Brizard; Dietger Niederwieser; Julie Freeman-Edward; Gavin Cuthbert; Nick Bown; Richard E Clark; Elizabeth P Nacheva; Anthony R Green; Michael W N Deininger
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

10.  Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9.

Authors:  Ayda Bennour; Halima Sennana; Mohamed Adnène Laatiri; Moez Elloumi; Abderrahim Khelif; Ali Saad
Journal:  Cancer Genet Cytogenet       Date:  2009-10
View more
  1 in total

1.  Discovering Genotype Variants in an Infant with VACTERL through Clinical Exome Sequencing: A Support for Personalized Risk Assessment and Disease Prevention.

Authors:  Gloria Pelizzo; Luigi Chiricosta; Emanuela Mazzon; Gian Vincenzo Zuccotti; Maria Antonietta Avanzini; Stefania Croce; Mario Lima; Placido Bramanti; Valeria Calcaterra
Journal:  Pediatr Rep       Date:  2021-01-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.